TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy.

Saved in:
Bibliographic Details
Title: TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy.
Authors: McNerney KO; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA., Karageorgos S; Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA, USA., Ferry GM; Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA, USA., Wolpaw AJ; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.; The Wistar Institute, Philadelphia, PA., Burudpakdee C; Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA, USA., Khurana P; Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA, USA., Toland CN; Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA, USA., Vemu R; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA., Vu A; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA., Hogarty MD; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA., Bassiri H; Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA, USA.; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Source: Oncoimmunology [Oncoimmunology] 2022 May 24; Vol. 11 (1), pp. 2075204. Date of Electronic Publication: 2022 May 24 (Print Publication: 2022).
Publication Type: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2162-402X
DOI:10.1080/2162402X.2022.2075204